Olga S.
- Country
- Spain
- Department
- 172417: Hematology and Hemotherapy
Research Overview
- Phase 1 Study of LAVA-1266, a CD123-Targeting Bispecific Vγ9Vδ2-T Cell Engager, in CD123 Positive R/R AML and Intermediate to Extremely High-Risk MDS Patients
- A Phase 1/2 Study of Enzomenib (DSP 5336) in Adults with Relapsed or Refractory Acute Leukemia, Including MLL-Rearranged or NPM1-Mutated Subtypes
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 169 of 383 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating complex blood disorders, with particular emphasis on acute myeloid leukemia (AML), focusing on cases that have become resistant to standard treatments or have relapsed.
- Relapsed/Refractory AML Management
- Higher-risk Myelodysplastic Syndrome (HR-MDS)
Their research extends to innovative therapeutic approaches for patients who have exhausted conventional treatment options.
Advanced Blood Disorders
A key area of focus includes the treatment of advanced systemic mastocytosis, investigating novel therapeutic agents to address this rare but serious condition.
- Systemic Mastocytosis Treatment
- Novel Therapeutic Development
The investigator works on developing targeted treatments for patients with advanced manifestations of the disease.
Therapeutic Innovation
The investigator explores novel compounds including tuspetinib and bezuclastinib, focusing on their application in treating resistant blood cancers.
- Drug Safety and Tolerability Studies
- Treatment Response Assessment
Their work encompasses evaluating new therapeutic agents' effectiveness in treating complex hematological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.